Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | TERT | O14746 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARD | Q03181 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041022 | 1.00 | FAAH (0.61) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL18587413 | 0.83 | FAAH (0.52) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL532713 | 0.82 | FAAH (0.63) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL532715 | 0.82 | FAAH (0.63) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL9212159 | 0.81 | FAAH (0.67) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL10608390 | 0.81 | FAAH (0.58) | FAAHCES1TERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL6565477 | 0.81 | FAAH (0.61) | FAAHCES1TERTPTPN1PPARG | |
| SCHEMBL15956273 | 0.81 | FAAH (0.61) | FAAHCES1TERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL6565479 | 0.81 | FAAH (0.61) | FAAHCES1TERTPTPN1PPARG | |
| Trimethylammonium SCHEMBL25400813 | 0.80 | FAAH (0.65) | FAAHCES1TERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1198256-A4 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CORP (US) | 2004-06-16 | — | — | EP | claimed |
| EP-0964690-B1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CO INC (US) | 2003-07-09 | — | — | EP | claimed |
| EP-0758883-B1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | LIPOSOME CO INC (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2001000247-A9 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CO INC (US) | 2002-08-29 | — | — | WO | claimed |
| EP-1198256-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME CORPORATION (US) | 2002-04-24 | — | — | EP | claimed |
| US-6339069-B1 | ADMINISTERING FORMULATION COMPRISING PHARMACEUTICALLY ACCEPTABLE CARRIER; AND, LIPOSOME COMPRISING A BIOACTIVE AGENT AND A LIPID COMPONENT, THE LIPID COMPONENT COMPRISING A PEPTIDE-LIPID CONJUGATE | ELAN PHARMACEUTICALSTECHNOLOGIES, INC. | 2002-01-15 | — | — | US | claimed |
| WO-2001000247-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 2001-01-04 | — | — | WO | claimed |
| US-6143716-A | CONTROLLED DELIVERY SYSTEM TO DELIVER LIPOSOMAL DRUGS IN VITRO OR IN VIVO, FOR EXAMPLE, IN TREATMENT OF MAMMALS AFFLICTED WITH VARIOUS DISEASES, DISORDERS OR CONDITIONS, E.G., CANCERS | THE LIPOSOME COMPANY, INC. (US) | 2000-11-07 | — | — | US | claimed |
| EP-0964690-A4 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | LIPOSOME CO INC (US) | 2000-03-29 | — | — | EP | claimed |
| EP-0964690-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1999-12-22 | — | — | EP | claimed |
| WO-1998016240-A1 | PEPTIDE-LIPID CONJUGATES, LIPOSOMES AND LIPOSOMAL DRUG DELIVERY | THE LIPOSOME COMPANY, INC. (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0758883-A1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | THE LIPOSOME CORPORATION (US) | 1997-02-26 | — | — | EP | claimed |
| US-5552155-A | Fusogenic lipsomes and methods for making and using same | THE LIPOSOME COMPANY, INC. (US) | 1996-09-03 | — | — | US | claimed |
| WO-1995027478-A1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | THE LIPOSOME COMPANY, INC. (US) | 1995-10-19 | — | — | WO | claimed |
| US-12551460-B2 | Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes | PDS BIOTECHNOLOGY COPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025235559-A1 | IL-12 FUSION PROTEIN FORMULATIONS AND METHODS OF USE THEREOF | PDS BIOTECHNOLOGY CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250281406-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2025-09-11 | — | — | US | disclosed |
| EP-0758883-A1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | THE LIPOSOME CORPORATION (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5552155-A | Fusogenic lipsomes and methods for making and using same | THE LIPOSOME COMPANY, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| WO-1995027478-A1 | FUSOGENIC LIPOSOMES AND METHODS OF MAKING AND USING SAME | THE LIPOSOME COMPANY, INC. (US) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281406-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | LIPA, LIPG, SGMS1 | FAAH 1024/4885CES1 270/4885TERT 2121/4885 |
| US-12551460-B2 | Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes | IFNAR1, STING1, IFNG | FAAH 3030/4885CES1 1819/4885TERT 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.